Lebrikizumab Shows Real-World Effectiveness for Moderate-to-Severe Atopic Dermatitis
A multicenter Italian study confirms lebrikizumab delivers meaningful skin, itch, and quality-of-life improvements in real-world AD patients over 24 weeks.
Résumé
A multicenter Italian observational study of 91 adults with moderate-to-severe atopic dermatitis found that lebrikizumab, a biologic targeting IL-13, achieved a 75% or greater reduction in eczema severity (EASI75) in nearly half of patients at 16 weeks, rising to 59% by week 24. Biologic- and JAK inhibitor-naive patients responded better than those with prior advanced therapy. Improvements in itch, sleep, and quality of life were also clinically meaningful. Side effects were mostly mild, with conjunctivitis being the most common adverse event, consistent with its mechanism of action. These findings support lebrikizumab as an effective and well-tolerated option in routine clinical practice.
Résumé détaillé
Atopic dermatitis is a chronic inflammatory skin condition driven heavily by IL-4 and IL-13 signaling. While clinical trials have established lebrikizumab — a monoclonal antibody selectively targeting IL-13 — as effective for moderate-to-severe disease, real-world data across diverse patient populations had remained sparse until this study.
Researchers at eight Italian university hospitals enrolled 91 adults with moderate-to-severe atopic dermatitis between March and December 2025. All patients received lebrikizumab for at least 16 weeks. The primary endpoint was achieving EASI75 (75% or greater improvement in the Eczema Area and Severity Index) at week 16, with secondary endpoints including EASI90, EASI100, pruritus scores, sleep quality ratings, and Dermatology Life Quality Index scores.
At week 16, 49.5% of patients achieved EASI75, 20.9% reached EASI90, and 9.9% achieved complete clearance (EASI100). By week 24, these rates improved to 58.6%, 32.8%, and 25.9%, respectively — suggesting continued therapeutic benefit beyond the initial induction phase. Patient-reported outcomes including itch severity and sleep disturbance also showed meaningful improvement.
Importantly, patients who were naive to prior biologics or JAK inhibitors showed numerically higher response rates compared to those with prior advanced therapy exposure. No significant differences in outcomes were observed based on age, sex, disease duration, or presence of atopic comorbidities such as asthma or allergic rhinitis. Adverse events occurred in 23.1% of patients and were predominantly mild to moderate; conjunctivitis was the most frequently reported, aligning with the known safety profile of IL-13-targeting agents.
These real-world findings largely mirror clinical trial results and provide reassurance about lebrikizumab's utility in heterogeneous patient populations. A key caveat is the relatively small sample size and short follow-up duration, limiting conclusions about long-term durability and rare adverse events.
Principales conclusions
- EASI75 achieved in 49.5% at week 16 and 58.6% at week 24 in real-world AD patients.
- Complete skin clearance (EASI100) rose from 9.9% at week 16 to 25.9% at week 24.
- Biologic- and JAK inhibitor-naive patients showed numerically superior response rates.
- Adverse events occurred in 23.1% of patients; conjunctivitis was the most common.
- Meaningful improvements in itch, sleep disturbance, and quality of life were sustained through week 24.
Méthodologie
This was a multicenter, retrospective observational study conducted at eight Italian university hospitals enrolling 91 adults with moderate-to-severe atopic dermatitis. Outcomes were assessed at baseline, week 16, and week 24 using validated clinical and patient-reported measures. No control arm was included, limiting causal inference.
Limites de l'étude
The study's relatively small sample of 91 patients and short 24-week follow-up limit conclusions about long-term efficacy and rare adverse events. The absence of a comparator arm prevents head-to-head effectiveness comparisons with dupilumab or tralokinumab. Retrospective observational design introduces potential for selection bias and confounding.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :